Search Result

Results for "

CGMP

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Deaminase (3) Adenosine Receptor (2) Adenylate Cyclase (2) Adrenergic Receptor (1) Akt (2) AMPK (1) Androgen Receptor (1) Angiotensin Receptor (3) Angiotensin-converting Enzyme (ACE) (1) Antibiotic (1) Apoptosis (11) Aquaporin (2) ATP Synthase (2) AUTACs (2) Autophagy (4) Bacterial (4) Biochemical Assay Reagents (3) Calcium Channel (13) Carbonic Anhydrase (3) Caspase (2) COX (1) Drug Derivative (2) Drug Intermediate (2) Drug Metabolite (2) Endogenous Metabolite (35) Endothelin Receptor (1) Environmental Pollutants (5) Fluorescent Dye (2) GABA Receptor (1) GLP Receptor (1) GPR35 (1) Guanylate Cyclase (32) HCN Channel (5) Heme Oxygenase (HO) (1) HSV (1) iGluR (6) Influenza Virus (3) Interleukin Related (2) Isotope-Labeled Compounds (7) Keap1-Nrf2 (1) Lysyl Oxidase (1) mAChR (1) MAPKAPK2 (MK2) (1) Microtubule/Tubulin (5) MMP (4) Monoamine Oxidase (9) Myosin (5) Natriuretic Peptide Receptor (NPR) (4) Neprilysin (1) Neurotensin Receptor (1) NF-κB (1) NO Synthase (21) NOD-like Receptor (NLR) (2) Nucleoside Antimetabolite/Analog (3) p38 MAPK (4) Parasite (8) Phosphodiesterase (PDE) (75) PI3K (2) PI4K (2) PKA (7) PKC (8) PKG (32) Potassium Channel (8) Pregnane X Receptor (PXR) (2) Prostaglandin Receptor (1) Reactive Oxygen Species (ROS) (2) Reference Standards (27) ROCK (4) Ser/Thr Protease (1) Sigma Receptor (2) TGF-beta/Smad (3) TGF-β Receptor (4) Wnt (1) α-synuclein (1) β-catenin (1)
By Research Areas:	Cancer (47) Cardiovascular Disease (71) Endocrinology (25) Infection (32) Inflammation/Immunology (48) Metabolic Disease (39) Neurological Disease (72)
Click Chemistry:	Alkynes (1)

227

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0442

Vardenafil 5 Publications Verification	Phosphodiesterase (PDE) Endogenous Metabolite	Metabolic Disease Inflammation/Immunology Endocrinology Cancer
Vardenafil is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-B1816

Zaprinast 3 Publications Verification M&B 22948	Phosphodiesterase (PDE) GPR35	Cardiovascular Disease Neurological Disease Endocrinology
Zaprinast (M&B 22948) is a selective inhibitor of cGMP-selective Phosphodiesterase (PDE5). Zaprinast causes a significant increase in cGMP levels in myocytes. Zaprinast is a G protein-coupled receptor 35 (GPR35) agonist which activates rat GPR35 strongly and activates human GPR35 moderately. Zaprinast reduces vessel remodeling through antiproliferative and proapoptotic effects .

HY-18252

Avanafil 1 Publications Verification TA1790	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite	Cardiovascular Disease Endocrinology
Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-B0442A

Vardenafil hydrochloride 5 Publications Verification	Phosphodiesterase (PDE) Endogenous Metabolite	Metabolic Disease Inflammation/Immunology Endocrinology Cancer
Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-101379A

*8-Bromo-cGMP* sodium** 5+ Cited Publications	Calcium Channel	Cardiovascular Disease Neurological Disease
8-Bromo-cGMP sodium, a membrane-permeable analogue of cGMP, is a PKG (protein kinase G) activator. 8-Bromo-cGMP sodium significantly inhibits Ca ²⁺ macroscopic currents and impairs insulin release stimulated with high K ⁺ . 8-Bromo-cGMP sodium has antinociceptive effects and results in vasodilator responses .

HY-B0442B

Vardenafil hydrochloride trihydrate 5 Publications Verification	Endogenous Metabolite Phosphodiesterase (PDE)	Metabolic Disease Inflammation/Immunology Endocrinology
Vardenafil hydrochloride trihydrate is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride trihydrate shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride trihydrate competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride trihydrate can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-101525

MBP146-78 3 Publications Verification	Parasite	Infection
MBP146-78 is a potent and selective inhibitor of *cGMP* dependent protein kinases.

HY-17500

Ataciguat 1 Publications Verification HMR-1766	Guanylate Cyclase	Cardiovascular Disease
Ataciguat (HMR-1766) is a nitric oxide-independent soluble guanylate cyclase (sGC) activator. Ataciguat is able to activate the ferric heme-iron redox form of sGC that stimulate the production of cyclic GMP (cGMP). Ataciguat exhibits vasodilator effects .

HY-109039

Praliciguat 2 Publications Verification IW-1973	Guanylate Cyclase Apoptosis	Cardiovascular Disease Metabolic Disease
Praliciguat (IW-1973) is a potent and orally active soluble guanylate cyclase (sGC) activator. Praliciguat can increases cGMP via the nitric oxide (NO)-sGC pathway. Praliciguat can inhibit the expression of proinflammatory cytokines and inhibit apoptosis. Praliciguat can promote vasodilation. Praliciguat can be used for the researches of metabolic disease and cardiovascular disease, such as hypertension, diabetes and heart failure .

HY-113469

Cyclic GMP 1 Publications Verification	Endogenous Metabolite	Infection Cardiovascular Disease Inflammation/Immunology
Cyclic GMP (cGMP), an important second messenger, is a major intracellular mediator of extracellular signals such as nitric oxide (NO) and natriuretic peptides (NPs). Effects of Cyclic GMP occur through three main groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and PDEs. Cyclic GMP can inhibit both platelet adhesion and aggregation. cGAMP (Cyclic-GMP-AMP) (HY-12512), a conjugate of Cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses .

HY-N8245

*2',3'-cGMP* sodium** Guanosine 2',3'-cyclic monophosphate sodium salt	Drug Intermediate	Others
2',3'-cGMP sodium, a cGMP analogue, is an intermediate of RNA catalytic cleavage by binase .

HY-W013386

LY83583 1 Publications Verification	Guanylate Cyclase	Cardiovascular Disease Neurological Disease Cancer
LY83583 is inhibitor of soluble guanylate cyclase (sGC) with the ability to target the *cGMP* signaling pathway. LY83583 inhibits the kinase activity-related proliferation of tumor cells by inducing the Cdk inhibitor p21. LY83583 can be used for the study of cancers (colorectal cancer, breast cancer and melanoma) and cardiovascular disease .

HY-100457

IC87201 2 Publications Verification	iGluR	Neurological Disease
IC87201, an inhibitor of PSD95-nNOS protein-protein interactions, suppresses NMDAR-dependent NO and cGMP formation.

HY-P1292

PKG inhibitor peptide 2 Publications Verification	PKG	Cancer
PKG inhibitor peptide is an ATP-competitive inhibitor of cGMP-dependent protein kinase (PKG), with a K_i of 86 μM .

HY-P2026

A 71915	Natriuretic Peptide Receptor (NPR)	Cardiovascular Disease
A 71915 is a highly potent and competitive natriuretic peptide receptor A (ANP, NPRA) antagonist (pK_i= 9.18). A 71915 displaces [ ¹²⁵I]ANP dose dependently, with a K_i of 0.65 nM. A71915( pA₂= 9.48) against rat ANP-induced cGMP production in NB-OK-1 cells .

HY-113469A

Cyclic GMP sodium 1 Publications Verification	Endogenous Metabolite	Infection Cardiovascular Disease Inflammation/Immunology
Cyclic GMP (cGMP) sodium, an important second messenger, is a major intracellular mediator of extracellular signals such as nitric oxide (NO) and natriuretic peptides (NPs). Effects of Cyclic GMP sodium occur through three main groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and PDEs. Cyclic GMP can inhibit both platelet adhesion and aggregation. cGAMP (Cyclic-GMP-AMP) (HY-12512), a conjugate of Cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses .

HY-114672

MBCQ	Phosphodiesterase (PDE)	Cardiovascular Disease
MBCQ is a potent and selective cGMP-specific phosphodiesterase (PDE V; PDE5) inhibitor with an IC₅₀ of 19 nM. MBCQ lacks inhibitory activity toward other PDE isozymes (all IC₅₀s>100 μM). MBCQ dilates coronary arteries via specific inhibition of cGMP-PDE .

HY-137494

Ethyl β-carboline-3-carboxylate	GABA Receptor	Neurological Disease
Ethyl β-carboline-3-carboxylate (fl-CCE) is a ligand and short-acting antagonist of benzodiazepine receptors. Ethyl β-carboline-3-carboxylate did not affect cerebellar cGMP levels when used alone, but when taken together with Diazepam, it significantly inhibited the cGMP levels that were upregulated by Diazepam .

HY-P2692B

DT-2 acetate 1 Publications Verification	PKG	Cancer
DT-2 is a potent and selective inhibitor of the cGMP-dependent protein kinase (PKG). DT-2 inhibits PKG catalyzed phosphorylation (K_i: 12.5 nM) .

HY-N8245R

*2',3'-cGMP* sodium (Standard)** Guanosine 2',3'-cyclic monophosphate sodium salt (Standard)	Drug Intermediate Reference Standards	Others
2',3'-cGMP sodium, a cGMP analogue, is an intermediate of RNA catalytic cleavage by binase .

HY-130354

*Dibutyryl-cGMP* sodium** 2 Publications Verification Bt2CGMP sodium	Potassium Channel	Cardiovascular Disease
Dibutyryl-cGMP sodium (Bt2cGMP sodium) is a cell-permeable cGMP analogue. Dibutyryl-cGMP sodium preferentially activates cGMP-dependent protein kinase (PKG). Dibutyryl-cGMP sodium inhibits the release of [ ³H]-arachidonic acid from γ thrombin-stimulated human platelets. Dibutyryl-cGMP sodium induces peripheral antinociception via activation of ATP-sensitive K ⁺ channels .

HY-137016A

*8-Pcpt-cGMP* sodium** 1 Publications Verification	HCN Channel	Neurological Disease
8-Pcpt-cGMP sodium is the sodium salt form of 8-Pcpt-cGMP (HY-137016). 8-Pcpt-cGMP sodium is an agonist for cyclic nucleotide-gated (CNG) channel with an EC₅₀ of 0.5 μM. 8-Pcpt-cGMP sodium exhibits good membrane permeability. 8-Pcpt-cGMP sodium can be used in studies about the function of CNG channels in visual signal transduction and olfactory transduction .

HY-108548

Rp-8-Br-PET-cGMPS sodium Rp-8-Bromo-PET-CGMPS	PKG	Inflammation/Immunology
Rp-8-Br-PET-cGMPS sodium (Rp-8-Bromo-PET-cGMPS) is an analog of cyclic GMP (cGMP). It is a cell permeable, competitive, and reversible inhibitor of cGMP-dependent protein kinases (cGKs) that blocks activation of cGKI and cGKII by cGMP (Kis=35 and 30 nM). It less potently inhibits protein kinase A (Ki=11 μM) and cGMP-induced activation of cyclic nucleotide-gated channels (IC₅₀=25 μM). In the absence of cGMP stimulation, Rp-8-bromo-PET-cGMPS can act as a partial agonist of cGKI (Ki=1 μM). Rp-8-bromo-PET-cGMPS is resistant to hydrolysis by phosphodiesterase 11.

HY-P0142A

DT-3 acetate	PKG	Cardiovascular Disease
DT-3 acetate is a membrane-permeable protein kinase G Iα (PKG Iα) inhibitory peptide and shows pharmacological blockade of the cGMP-PKG signalling .

HY-133869

cGMP-HTL CGMP-HaloTag-ligand	Autophagy	Cancer
cGMP-HTL contains a HT-ligand, a linker and the Cys-S-cGMP (autophagy tag). cGMP-HTL increases the K63-linked ubiquitination of mitochondria. AUTAC (autophagy-targeting chimera) is a novel targeted-clearance strategy that contains a degradation tag (guanine derivatives) and a warhead to provide target specificity .

HY-134345

*8-pCPT-cGMP-AM* 8-(4-Chlorophenylthio)-CGMP-AM	PKG	Neurological Disease
8-pCPT-cGMP-AM (8-(4-Chlorophenylthio)-cGMP-AM) is a highly membrane permeable prodrug of the PKG agonist 8-pCPT-cGMP, which increases the membrane permeability of cGMP and is converted to its active form by esterase hydrolysis within the cell, thereby activating PKG. 8-pCPT-cGMP-AM can be used to explore the role of cGMP signaling in neural plasticity and memory formation .

HY-110221

Rp-8-pCPT-cGMPS sodium 1 Publications Verification	PKG	Neurological Disease
Rp-8-pCPT-cGMPS sodium is the sodium salt form of Rp-8-pCPT-cGMPS. Rp-8-pCPT-cGMPS is an inhibitor for cGMP-dependent protein kinase (cGK). Rp-8-pCPT-cGMPS sodium is an agonist for cyclic nucleotide-gated (CNG) channels in a voltage-dependent manner .

HY-135110

Rp-8-Br-cGMPS sodium 1 Publications Verification Rp-8-bromo-Cyclic GMPS sodium	Calcium Channel PKG HCN Channel	Metabolic Disease
Rp-8-Br-cGMPS (Rp-8-bromo-Cyclic GMPS) sodium salt is a potent Ca ²⁺-ATPase activator. Rp-8-Br-cGMPS is also an agonist of the rod CNG channel and an inhibitor of PKG. Rp-8-Br-cGMPS sodium salt mediates cytosolic Ca ²⁺ reduction by activating Ca ²⁺-ATPase and subsequently removing Ca ²⁺ from the cell .

HY-113469B

Cyclic GMP (TBAOH)	Endogenous Metabolite	Infection Cardiovascular Disease Inflammation/Immunology
Cyclic GMP (cGMP) TBAOH, an important second messenger, is a major intracellular mediator of extracellular signals such as nitric oxide (NO) and natriuretic peptides (NPs). Effects of Cyclic GMP TBAOH occur through three main groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and PDEs. Cyclic GMP can inhibit both platelet adhesion and aggregation. cGAMP (Cyclic-GMP-AMP) (HY-12512), a conjugate of Cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses .

HY-113469R

Cyclic GMP (Standard)	Endogenous Metabolite Reference Standards	Infection Cardiovascular Disease Inflammation/Immunology
Cyclic GMP (Standard) is the analytical standard of Cyclic GMP (HY-113469). This product is intended for research and analytical applications. Cyclic GMP (cGMP), an important second messenger, is a major intracellular mediator of extracellular signals such as nitric oxide (NO) and natriuretic peptides (NPs). Effects of Cyclic GMP occur through three main groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and PDEs. Cyclic GMP can inhibit both platelet adhesion and aggregation. cGAMP (Cyclic-GMP-AMP) (HY-12512), a conjugate of Cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses .

HY-N1798

Quercetin 3,7-dimethyl ether 2 Publications Verification	Endogenous Metabolite	Cardiovascular Disease
Quercetin 3,7-dimethyl ether, isolated from Croton schiedeanus Schlecht, has a NO/cGMP pathway-related profile, with increased vasorelaxant activity .

HY-137665

PET-cGMP	PKG	Cardiovascular Disease
PET-cGMP is a cyclic guanosine monophosphate analog and an effective selective agonist of PKG I, the EC₅₀ of PET-cGMP for PKG Iβ is 3.8 nM, while for PKG II, it's 193 nM .

HY-121381

Kuraridine	Phosphodiesterase (PDE)	Others
Kuraridine is a prenylated flavonol extract from the roots of Sophora flavescens. Kuraridine has an inhibitory effect on cGMP specific phosphodiesterase type 5 (PDE5) (IC₅₀=0.64 μM) .

HY-102043

PDM-631	Phosphodiesterase (PDE)	Neurological Disease
PDM-631 is a selective and orally active PDE2A inhibitor with blood-brain barrier penetration. PDM-631 exhibits potent inhibitory activity against human and rat recombinant PDE2A with IC₅₀ values of 1.5 nM and 4.2 nM, respectively. PDM-631 increases cGMP levels in the rat cerebral cortex. PDM-631 can be used for the study of schizophrenia and neurodegenerative disorders .

HY-B0442AS

Vardenafil-d5 hydrochloride	Endogenous Metabolite Phosphodiesterase (PDE) Isotope-Labeled Compounds	Metabolic Disease Inflammation/Immunology Endocrinology
Vardenafil-d₅ hydrochloride is deuterated labeled Vardenafil hydrochloride (HY-B0442A). Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-P11380

Capa-2	Neurotensin Receptor Calcium Channel NO Synthase Guanylate Cyclase	Neurological Disease Metabolic Disease
Capa-2 is a neuropeptide. Capa-2 activates calcium ion influx, stimulates the production of NO, activates soluble guanylate cyclase (sGC), increases intracellular cGMP, and drives ion and fluid secretion. Capa-2 can be used in studies of diuresis .

HY-137108

Sp-8-pCPT-cGMPS	PKA PKG	Neurological Disease
Sp-8-pCPT-cGMPS is a potent cyclic guanosine monophosphate-gated channel agonist and a lipophilic activator of protein kinase G (types I α, I β, and II) and protein kinase A type II with excellent cell membrane permeability and phosphodiesterase stability. Sp-8-pCPT-cGMPS can be used to study the role of cGMP in neural plasticity and synaptic transmission .

HY-134271

*8-Br-cGMP-AM*	PKG	Cardiovascular Disease
8-Br-cGMP-AM is a derivative of 8-Br-cGMP. As an activator of PKG (cGMP-dependent protein kinase), it can lead to a variety of biological effects such as vasodilation and platelet inhibition. 8-Br-cGMP-AM can be used in the study of cardiovascular diseases .

HY-P1561

PKG Substrate	PKG	Neurological Disease
PKG Substrate is a selective substrate for cGMP-dependent protein kinase (PKG).

HY-P0142

DT-3	PKG	Cardiovascular Disease
DT-3 is a membrane-permeable protein kinase G Iα (PKG Iα) inhibitory peptide and shows pharmacological blockade of the cGMP-PKG signalling .

HY-134314

8-Nitro-cGMP	Autophagy Endogenous Metabolite Nucleoside Antimetabolite/Analog	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
8-Nitro-cGMP is an electrophilic second messenger of redox signaling that can form a protein-S-cGMP adduct in s-guanylation process. 8-Nitro-cGMP is an autophagy inducer. 8-Nitro-cGMP promotes RANKL-induced osteoclast differentiation from macrophages. 8-Nitro-cGMP has vasodilator effect, and ameliorates the vascular endothelial dysfunction in diabetic mice .

HY-137016

8-Pcpt-cGMP	HCN Channel	Neurological Disease
8-Pcpt-cGMP is an agonist for cyclic nucleotide-gated (CNG) channel with an EC₅₀ of 0.5 μM. 8-Pcpt-cGMP exhibits good membrane permeability. 8-Pcpt-cGMP can be used in studies about the function of CNG channels in visual signal transduction and olfactory transduction .

HY-P10720

C-Type Natriuretic Peptide (1-53), Porcine, Rat,mouse	Endogenous Metabolite	Cardiovascular Disease
C-Type Natriuretic Peptide (1-53), Porcine, Rat, mouse is an activator of particulate guanylate cyclase B (pGC-B), which is highly expressed in endothelial cells, kidneys, and the heart. C-Type Natriuretic Peptide (1-53), Porcine, Rat, mouse can mediate a potent anti-fibrotic effect in human cardiac and renal fibroblasts by generating the second messenger *cGMP* .

HY-117390

FR-181074	Phosphodiesterase (PDE)	Cardiovascular Disease Metabolic Disease
FR-181074 is a selective and orally active PDE V inhibitor. FR-181074 can specifically block PDE V to inhibit the degradation of cyclic guanosine monophosphate (cGMP) in order to relax smooth muscle. FR-181074 can be used for the researches of cardiovascular disease and endocrinology, such as hypertension and erectile dysfunction .

HY-131737

1-NH2-cGMP	PKG	Others
1-NH2-cGMP is an analog of cGMP .

HY-131764

*2'-O-MB-cGMP* sodium** 2′-O-Monobutyryl-CGMP sodium	Phosphodiesterase (PDE)	Others
2'-O-MB-cGMP (2′-O-Monobutyryl-cGMP) sodium is a cyclic GMP-specific phosphodiesterase inhibitor with an I₅₀ value of 35 µM. 2'-O-MB-cGMP (2′-O-Monobutyryl-cGMP) sodium inhibits Ca ²⁺ dependent phosphodiesterase hydrolysis using cAMP or cGMP as substrate .

HY-137373

Rp-8-pCPT-cGMPS	PKG	Others
Rp-8-pCPT-cGMPS is a competitive inhibitor of cGMP-dependent protein kinase (PKG) (K_i=0.5 μM). Rp-8-pCPT-cGMPS has high lipid solubility and can more easily penetrate the cell membrane and reach sufficient concentration inside the cell to inhibit cGMP-dependent protein kinase. Rp-8-pCPT-cGMPS can be used to study the activity and function of cGMP-dependent protein kinase in platelets .

HY-137378A

8-Br-PET-cGMP	PKG	Cardiovascular Disease Inflammation/Immunology
8-Br-PET-cGMP is an agonist of cGMP-dependent protein kinase type I (cGKI). 8-Br-PET-cGMP promotes the dimerization of cGKI and activates its catalytic activity by binding to the regulatory domain of cGKI. 8-Br-PET-cGMP can be used to study the role of cGMP signaling pathways in cell growth, vasodilation, and smooth muscle cell function .

HY-134311

8-NBD-cGMP	Fluorescent Dye	Others
8-NBD-cGMP is a fluorescent analog of cyclic guanosine monophosphate and a potent, membrane-permeable, fluorescent activator of cGMP-dependent protein kinase isozymes I α and I β. 8-NBD-cGMP is barely fluorescent in aqueous solution but fluoresces strongly in hydrophobic environments such as hydrophobic protein binding sites

HY-W767865

Cyclic GMP sodium-13C5	Isotope-Labeled Compounds Endogenous Metabolite	Infection Cardiovascular Disease Inflammation/Immunology
Cyclic GMP sodium- ¹³C₅ is the ¹³C-labeled Cyclic GMP sodium (HY-113469A). Cyclic GMP (cGMP) sodium, an important second messenger, is a major intracellular mediator of extracellular signals such as nitric oxide (NO) and natriuretic peptides (NPs). Effects of Cyclic GMP sodium occur through three main groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and PDEs. Cyclic GMP can inhibit both platelet adhesion and aggregation. cGAMP (Cyclic-GMP-AMP) (HY-12512), a conjugate of Cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses .

Cat. No.	Product Name	Type

HY-14536

Methylene Blue

25+ Cited Publications

Basic Blue 9; CI-52015; Methylthioninium chloride

Fluorescent Dye

Methylene blue (Basic Blue 9) is a guanylyl cyclase (sGC), monoamine oxidase A (MAO-A) and NO synthase (NOS) inhibitor. Methylene blue is a vasopressor and is often used as a dye in several medical procedures. Methylene blue through the nitric oxide syntase/guanylate cyclase signalling pathway to reduce prepulse inhibition. Methylene blue is a REDOX cycling compound and able to cross the blood-brain barrier. Methylene blue is a Tau aggregation inhibitor. Methylene Blue is a photosensitizer and redox agent. Methylene blue reduces cerebral edema, attenuated microglial activation and reduced neuroinflammation .

HY-14536A

Methylene blue (purity≥70%)

Basic Blue 9 (purity≥70%); CI-52015 (purity≥70%); Methylthioninium chloride (purity≥70%)

Fluorescent Dye

Methylene blue (purity≥70%) is a guanylyl cyclase (sGC), monoamine oxidase A (MAO-A) and NO synthase (NOS) inhibitor. Methylene blue (purity≥70%) is a vasopressor and is often used as a dye in several medical procedures. Methylene blue (purity≥70%) through the nitric oxide syntase/guanylate cyclase signalling pathway to reduce prepulse inhibition. Methylene blue (purity≥70%) is a REDOX cycling compound and able to cross the blood-brain barrier. Methylene blue (purity≥70%) is a Tau aggregation inhibitor. Methylene blue reduces cerebral edema, attenuated microglial activation and reduced neuroinflammation .

HY-14536R

Methylene Blue (Standard)

Basic Blue 9 (Standard); CI-52015 (Standard); Methylthioninium chloride (Standard)

Fluorescent Dye

Methylene Blue (Standard) is the analytical standard of Methylene Blue. This product is intended for research and analytical applications. Methylene blue (Basic Blue 9) is a guanylyl cyclase (sGC), monoamine oxidase A (MAO-A) and NO synthase (NOS) inhibitor. Methylene blue is a vasopressor and is often used as a dye in several medical procedures. Methylene blue through the nitric oxide syntase/guanylate cyclase signalling pathway to reduce prepulse inhibition. Methylene blue is a REDOX cycling compound and able to cross the blood-brain barrier. Methylene blue is a Tau aggregation inhibitor. Methylene blue reduces cerebral edema, attenuated microglial activation and reduced neuroinflammation .

Cat. No.	Product Name	Type

HY-Y1325I

Sodium acetate trihydrate, 99.5%

Biochemical Assay Reagents

Sodium acetate trihydrate, 99.5% is a short-chain fatty acid salt with multiple biological activities. Sodium acetate trihydrate, 99.5% serves as a direct precursor of acetyl-CoA, and it extensively affects gene expression by promoting histone acetylation. Sodium acetate trihydrate, 99.5% can activate the p38 MAPK pathway to induce cancer cell apoptosis. Sodium acetate trihydrate, 99.5% can activate the Wnt/β-catenin signaling pathway to stimulate the proliferation and migration of cecal epithelial cells, thereby improving intestinal health. Sodium acetate trihydrate, 99.5% alleviates lead accumulation and oxidative damage by upregulating the testosterone-dependent eNOS/NO/cGMP signaling pathway, as well as activating the Nrf2/HO-1 pathway and its downstream antioxidant enzymes .

HY-134256

8-APT-cGMP	Biochemical Assay Reagents
8-APT-cGMP is a biochemical reagent that can be used as a biological material or organic compound for life science related research.

Cat. No.	Product Name	Target	Research Area

HY-108741

Plecanatide	Guanylate Cyclase	Inflammation/Immunology Cancer
Plecanatide, an analogue of Uroguanylin, is an orally active guanylate cyclase-C (GC-C) receptor agonist. Plecanatide activates GC-C receptors to stimulate cGMP synthesis with an EC₅₀ of 190 nM in T84 cells assay. Plecanatide shows anti-inflammatory activity in models of murine colitis .

HY-108741A

Plecanatide acetate	Guanylate Cyclase	Inflammation/Immunology Cancer
Plecanatide acetate, an analogue of Uroguanylin, is an orally active guanylate cyclase-C (GC-C) receptor agonist. Plecanatide acetate activates GC-C receptors to stimulate cGMP synthesis with an EC₅₀ of 190 nM in T84 cells assay. Plecanatide acetate can be used for the research of chronic idiopathic constipation, and it also shows anti-inflammatory activity in models of murine colitis .

HY-P1292

PKG inhibitor peptide 2 Publications Verification	PKG	Cancer
PKG inhibitor peptide is an ATP-competitive inhibitor of cGMP-dependent protein kinase (PKG), with a K_i of 86 μM .

HY-P2026

A 71915	Natriuretic Peptide Receptor (NPR)	Cardiovascular Disease
A 71915 is a highly potent and competitive natriuretic peptide receptor A (ANP, NPRA) antagonist (pK_i= 9.18). A 71915 displaces [ ¹²⁵I]ANP dose dependently, with a K_i of 0.65 nM. A71915( pA₂= 9.48) against rat ANP-induced cGMP production in NB-OK-1 cells .

HY-P2692B

DT-2 acetate 1 Publications Verification	PKG	Cancer
DT-2 is a potent and selective inhibitor of the cGMP-dependent protein kinase (PKG). DT-2 inhibits PKG catalyzed phosphorylation (K_i: 12.5 nM) .

HY-P0142A

DT-3 acetate	PKG	Cardiovascular Disease
DT-3 acetate is a membrane-permeable protein kinase G Iα (PKG Iα) inhibitory peptide and shows pharmacological blockade of the cGMP-PKG signalling .

HY-P1179A

Guanylin(human) TFA	Guanylate Cyclase Endogenous Metabolite	Metabolic Disease
Guanylin(human) TFA, a 15-amino acid peptide, is an endogenous intestinal guanylate cyclase activator. Guanylin(human) TFA is mainly found in gastrointestinal tract which regulates electrolytead water transport in intestinal and renal epithelia through cyclic GMP-dependent mechanism .

HY-P1179

Guanylin(human)	Guanylate Cyclase Endogenous Metabolite	Endocrinology Cancer
Guanylin(human), a 15-amino acid peptide, is an endogenous intestinal guanylate cyclase activator. Guanylin(human) is mainly found in gastrointestinal tract which regulates electrolytead water transport in intestinal and renal epithelia through cyclic GMP-dependent mechanism .

HY-P3624

Cenderitide	Guanylate Cyclase	Cardiovascular Disease
Cenderitide is a potent agonist of particulate guanylyl cyclase receptor (pGC). Cenderitide is a natriuretic peptide (NP) composed of C-type natriuretic peptide (CNP) fused to the C-terminus of Dendroaspis natriuretic peptide (DNP). Cenderitide activates both pGC-A and pGC-B, activates the second messenger *cGMP, suppresses aldosterone*, and preserves GFR without reducing blood pressure. Cenderitide can be used for heart failure research .

HY-P2281A

Atrial natriuretic factor (1-28) (human, porcine) TFA 1 Publications Verification Atrial natriuretic peptide (1-28) TFA	Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
Atrial natriuretic factor (1-28) (human, porcine) TFA exhibits blood pressure lowering activity by increasing sodium and urine excretion. Atrial natriuretic factor (1-28) (human, porcine) TFA inhibits the release of pituitary adrenocorticotropic hormone (ACTH) and beta-endorphin through inhibition of pro-opiomelanocortin (POMC) expression. Atrial natriuretic factor (1-28) (human, porcine) TFA increases cGMP levels in RMIC cells with an IC₅₀ of 1.2 nM .

HY-P11380

Capa-2	Neurotensin Receptor Calcium Channel NO Synthase Guanylate Cyclase	Neurological Disease Metabolic Disease
Capa-2 is a neuropeptide. Capa-2 activates calcium ion influx, stimulates the production of NO, activates soluble guanylate cyclase (sGC), increases intracellular cGMP, and drives ion and fluid secretion. Capa-2 can be used in studies of diuresis .

HY-P1561

PKG Substrate	PKG	Neurological Disease
PKG Substrate is a selective substrate for cGMP-dependent protein kinase (PKG).

HY-P0142

DT-3	PKG	Cardiovascular Disease
DT-3 is a membrane-permeable protein kinase G Iα (PKG Iα) inhibitory peptide and shows pharmacological blockade of the cGMP-PKG signalling .

HY-P1556

Vasonatrin Peptide (VNP)	PKG	Cardiovascular Disease
Vasonatrin Peptide (VNP) is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP). Vasonatrin peptide possesses the venodilating actions of CNP, the natriuretic actions of ANP, and unique arterial vasodilating actions not associated with either ANP or CNP. Vasonatrin Peptide protects the diabetic heart against ischemia-reperfusion injury by inhibiting ER stress via the cGMP-PKG signaling pathway .

HY-P10720

C-Type Natriuretic Peptide (1-53), Porcine, Rat,mouse	Endogenous Metabolite	Cardiovascular Disease
C-Type Natriuretic Peptide (1-53), Porcine, Rat, mouse is an activator of particulate guanylate cyclase B (pGC-B), which is highly expressed in endothelial cells, kidneys, and the heart. C-Type Natriuretic Peptide (1-53), Porcine, Rat, mouse can mediate a potent anti-fibrotic effect in human cardiac and renal fibroblasts by generating the second messenger *cGMP* .

HY-P3931

Histone H2b(29-35)	Peptides	Others
Histone H2b(29-35) is a synthetic heptapeptide that used as a substrate for cGMP-dependant kinase .

HY-P2692A

DT-2	Peptides	Cancer
DT-2 is a potent and selective inhibitor of the cGMP-dependent protein kinase (PKG). DT-2 inhibits PKG catalyzed phosphorylation (K_{i_{: 12.5 nM) .}}

HY-P3774

[Tyr8]-Atrial Natriuretic Peptide (5-27), rat	Natriuretic Peptide Receptor (NPR)	Cardiovascular Disease Endocrinology
[Tyr8]-Atrial Natriuretic Peptide (5-27), rat is an atrial natriuretic peptide (ANP) analog that relaxes smooth muscle without affecting cGMP levels .

HY-P2281

Atrial natriuretic factor (1-28) (human, porcine) Atrial natriuretic peptide (1-28)	Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
Atrial natriuretic factor (1-28) (human, porcine) exhibits blood pressure lowering activity by increasing sodium and urine excretion. Atrial natriuretic factor (1-28) (human, porcine) inhibits the release of pituitary adrenocorticotropic hormone (ACTH) and beta-endorphin through inhibition of pro-opiomelanocortin (POMC) expression. Atrial natriuretic factor (1-28) (human, porcine) increases cGMP levels in RMIC cells with an IC₅₀ of 1.2 nM .

HY-P1292A

PKG inhibitor peptide TFA	PKG	Cancer
PKG inhibitor peptide TFA is an ATP-competitive inhibitor of cGMP-dependent protein kinase (PKG), with a K_i of 86 μM .

HY-P1987

Mast cell degranulating peptide (28-49)	Calcium Channel	Neurological Disease
Mast cell degranulating peptide (28-49) is a depolarizing agent from bee venom, it can raise the content of *cGMP* level in mouse cerebellar slices .

HY-P1556A

Vasonatrin Peptide (VNP) TFA	PKG	Metabolic Disease
Vasonatrin Peptide (VNP) TFA is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP). Vasonatrin peptide TFA possesses the venodilating actions of CNP, the natriuretic actions of ANP, and unique arterial vasodilating actions not associated with either ANP or CNP. Vasonatrin Peptide TFA protects the diabetic heart against ischemia-reperfusion injury by inhibiting ER stress via the cGMP-PKG signaling pathway .

HY-P10869

dCNP 1 Publications Verification	Natriuretic Peptide Receptor (NPR)	Inflammation/Immunology Cancer
dCNP binds to NPR-B/C receptor, activates *cGMP* signaling pathway, and regulates vascular function. dCNP exhibits anti-hypoxia property through downregulation of hypoxia-related genes expressions like HIF1α and HIF2α. dCNP inhibits the induction of tumor stroma and exhibits anti-fibrosis activity. dCNP upregulates CTLs, NK cells, and conventional type 1 dendritic cells in tumors, and activates immune responses .

HY-P11184

CAP2b	Peptides	Others
CAP2b is a cardioacceleratory peptide that can be isolated from Drosophila. CAP2b stimulates tubule fluid secretion via cGMP-signaling pathway .

Cat. No.	Product Name	Target	Research Area	Image

HY-P990951

Vixticibart REGN-5381	Natriuretic Peptide Receptor (NPR)	Cardiovascular Disease
Vixticibart (REGN-5381) is a fully human IgG4 monoclonal antibody and NPR1 agonist that targets NPR1. Vixticibart stabilizes the receptor in an activated conformation by binding to the N-terminal domain of NPR1, and enhances the activity of endogenous ligands ANP and BNP without blocking ligand binding when these ligands are present. Vixticibart exerts vasodilatory and hypotensive effects by inducing *cGMP* production, preferentially dilating venous vessels to reduce systolic and venous pressure, but does not induce diuresis and may trigger a compensatory increase in heart rate. Vixticibart produces a synergistic hypotensive effect when combined with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and is currently mainly used in research related to heart failure and hypertension .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B1142

Lipoamide Maximum Cited Publications 9 Publications Verification (±)-α-Lipoamide; DL-Lipoamide; DL-6,8-Thioctamide	Natural Products Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Other Diseases Endogenous metabolite Disease Research Fields Source Classification	NO Synthase
Lipoamide ((±)-α-Lipoamide) is a monocarboxylic acid derivative of a neutral amide, formed by the condensation of the carboxyl group of lipoic acid and ammonia. Lipoamide protects against oxidative stress-mediated neuronal cell damage and also acts as a coenzyme to transfer acetyl groups and hydrogen during pyruvate deacylation. Lipoamide also stimulates mitochondrial biogenesis in adipocytes through the endothelial NO synthase-cGMP-protein kinase G signaling pathway .

HY-B0442

Vardenafil 5 Publications Verification	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Phosphodiesterase (PDE) Endogenous Metabolite
Vardenafil is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-18252

Avanafil 1 Publications Verification TA1790	Cardiovascular Disease Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite
Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-B0442A

Vardenafil hydrochloride 5 Publications Verification	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Phosphodiesterase (PDE) Endogenous Metabolite
Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-Y0488A

Formic acid ammonium 2 Publications Verification Ammonium formate	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Environmental Pollutants Calcium Channel NO Synthase Bacterial ATP Synthase
Formic acid ammonium is the ammonium salt form of formic acid, which is an endogenous metabolite. Formic acid ammonium activates the nitric oxide/cyclic guanosine monophosphate (NO/cGMP) signaling pathway in endothelial cells and inhibits calcium ion influx in vascular smooth muscle cells, resulting in vasomotor relaxation. Formic acid ammonium inhibits cytochrome C oxidase (CcO) and disrupts the electron transport chain, leading to ATP depletion. Formic acid ammonium can be used as a feed additive, which can lower the feed pH value, inhibit the growth of microorganisms (such as Escherichia coli, Salmonella), and extend the shelf life of the feed .

HY-B0442B

Vardenafil hydrochloride trihydrate 5 Publications Verification	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Endogenous Metabolite Phosphodiesterase (PDE)
Vardenafil hydrochloride trihydrate is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride trihydrate shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride trihydrate competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride trihydrate can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-N7126

Citronellal	Structural Classification Ketones, Aldehydes, Acids Murraya paniculata (L.) Jack. Rutaceae Plants Source Classification	Environmental Pollutants Potassium Channel
Citronellal is a monoterpene that can be found in the essential oils in various aromatic species of plants, with antiinflammatory and antinociceptive properties. Citronellal attenuates mechanical nociception, mediated in part by the NO-cGMP-ATP-sensitive K+ channel pathway. Citronellal induces reduction of spontaneuous activity, ataxia, analgesia, and sedation in vivo. Citronellal can attenuate mechanical nociception response in mouse model .

HY-N1860

3-O-Methylquercetin	Flavonoids Classification of Application Fields Flavones Aconitum apetalum (Huth) B. Fedtsch. Plants Rhamnaceae Inflammation/Immunology Disease Research Fields	Phosphodiesterase (PDE) NO Synthase
3-O-Methylquercetin is an inhibitor of cAMP and CGMP-phosphodiesterase (PDE) with IC₅₀ at 13.8 μM and 14.3 μM, respectively. 3-O-Methylquercetin is an inhibitor of β-secretase with an IC₅₀ of 6.5 μM. 3-O-Methylquercetin has a neuroprotective effect against neuronal death caused by oxidative damage. 3-O-Methylquercetin has strong antiviral activity against poliovirus, coxsackie virus and human rhinovirus. 3-O-Methylquercetin has anti-inflammatory and trachea-relaxing effects and can be used in the study of inflammatory diseases and asthma .

HY-113469

Cyclic GMP 1 Publications Verification	Natural Products Human Gut Microbiota Metabolites Microorganisms Endogenous metabolite Source Classification	Endogenous Metabolite
Cyclic GMP (cGMP), an important second messenger, is a major intracellular mediator of extracellular signals such as nitric oxide (NO) and natriuretic peptides (NPs). Effects of Cyclic GMP occur through three main groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and PDEs. Cyclic GMP can inhibit both platelet adhesion and aggregation. cGAMP (Cyclic-GMP-AMP) (HY-12512), a conjugate of Cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses .

HY-114367

Delphinidin 3-rutinoside chloride 1 Publications Verification Delphinidin 3-O-rutinoside chloride	Structural Classification Anthocyans Flavonoids Solanum melongena L. Classification of Application Fields Phenols Polyphenols Solanaceae Plants Disease Research Fields Source Classification Cancer	Endothelin Receptor NO Synthase Myosin GLP Receptor
Delphinidin 3-rutinoside chloride is an anthocyanin component. Delphinidin 3-rutinoside chloride is isolable from the fruits of blackcurrant Ribes nigrum L. Delphinidin 3-rutinoside chloride activates the ET_B receptor and stimulates the NO/cGMP pathway. Delphinidin 3-rutinoside chloride increases cyclic guanosine monophosphate production and reduces the phosphorylation level of Myosin regulatory light chain. Delphinidin 3-rutinoside chloride stimulates GLP-1 secretion. It significantly induces relaxation of bovine ciliary muscle strips contracted by ET-1 and inhibits ET-1-induced contraction of bovine ciliary muscle strips. Delphinidin 3-rutinoside chloride is applicable to research related to type 2 diabetes .

HY-N2374

Eupatorin 2 Publications Verification	Structural Classification Flavonoids Classification of Application Fields Flavones Cruciferae Phenols Polyphenols Isatis tinctoria L. Plants Disease Research Fields Source Classification Cancer	Apoptosis NF-κB MMP Adrenergic Receptor
Eupatorin is an orally active flavonoid with antiproliferative and vasodilatory properties. Eupatorin downregulates the expression levels of NF-κB, MMP9, IL-1β and TNF-α. Eupatorin induces apoptosis, G2/M phase cell cycle arrest, and reactive oxygen species (ROS) production. Eupatorin modulates the activities of muscarinic receptors and β-adrenergic receptors; inhibits sarcoplasmic reticulum calcium release and calcium channels; and activates the NO/sGC/cGMP pathway, indomethacin-sensitive pathway, and potassium channel pathway. Eupatorin exerts cytotoxic effects on cancer cell lines, and is metabolized by CYP1A1 and CYP1 family enzymes to form metabolites with antiproliferative activity. Eupatorin can be used in research related to breast cancer, hypertension, and leukemia .

HY-N4246

Bacopaside I	Triterpenes Structural Classification Terpenoids Scrophulariaceae Plants Bacopa monnieri (Linn.) Wettst. Source Classification	Aquaporin PKC Akt PI3K Apoptosis Monoamine Oxidase Pregnane X Receptor (PXR)
Bacopaside I is an orally active aquaporin AQP1 inhibitor and PKC modulator with neuroprotective and anticancer activities. Bacopaside I specifically blocks the water channel and *cGMP*-gated ion channel activities of AQP1 without affecting AQP4, thereby inhibiting the migration of colon cancer cells expressing AQP1. Bacopaside I activates the Akt pathway by interacting with PI3K, specifically inhibits MAO-A, effectively alleviates neuron necrosis and apoptosis induced by oxygen-glucose deprivation, reduces oxidative stress, and regulates the surface expression of neuroreceptors. When combined with Bacopaside II (HY-N6016), Bacopaside I significantly reduces the viability, proliferation and invasion ability of breast cancer cells, and binds to the pregnane X receptor (PXR). Bacopaside I is applicable to the research of colon cancer, breast cancer, vascular dementia, cerebral ischemia and other related diseases .

HY-113469A

Cyclic GMP sodium 1 Publications Verification	Natural Products Classification of Application Fields Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Endogenous Metabolite
Cyclic GMP (cGMP) sodium, an important second messenger, is a major intracellular mediator of extracellular signals such as nitric oxide (NO) and natriuretic peptides (NPs). Effects of Cyclic GMP sodium occur through three main groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and PDEs. Cyclic GMP can inhibit both platelet adhesion and aggregation. cGAMP (Cyclic-GMP-AMP) (HY-12512), a conjugate of Cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses .

HY-N0097R

Guanosine (Standard) DL-Guanosine (Standard); Vernine (Standard)	Structural Classification Natural Products Human Gut Microbiota Metabolites Immune System Disorder Microorganisms Disease markers Endocrine diseases Endogenous metabolite Source Classification	Reference Standards HSV Endogenous Metabolite
Guanosine (Standard) is the analytical standard of Guanosine. This product is intended for research and analytical applications. Guanosine (DL-Guanosine) is a purine nucleoside comprising guanine attached to a ribose (ribofuranose) ring via a β-N9-glycosidic bond. Guanosine possesses anti-HSV activity. In Vitro: Guanosine can be phosphorylated to become guanosine monophosphate (GMP), cyclic guanosine monophosphate (cGMP), guanosine diphosphate (GDP), and guanosine triphosphate (GTP). These forms play important roles in various biochemical processes such as synthesis of nucleic acids and proteins, photosynthesis, muscle contraction, and intracellular signal transduction (cGMP).

HY-113469R

Cyclic GMP (Standard)	Structural Classification Natural Products Human Gut Microbiota Metabolites Microorganisms Endogenous metabolite Source Classification	Endogenous Metabolite Reference Standards
Cyclic GMP (Standard) is the analytical standard of Cyclic GMP (HY-113469). This product is intended for research and analytical applications. Cyclic GMP (cGMP), an important second messenger, is a major intracellular mediator of extracellular signals such as nitric oxide (NO) and natriuretic peptides (NPs). Effects of Cyclic GMP occur through three main groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and PDEs. Cyclic GMP can inhibit both platelet adhesion and aggregation. cGAMP (Cyclic-GMP-AMP) (HY-12512), a conjugate of Cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses .

HY-N1798

Quercetin 3,7-dimethyl ether 2 Publications Verification	Cardiovascular Disease Flavonols Flavonoids Classification of Application Fields Croton tiglium Linn. Phenols Polyphenols Euphorbiaceae Plants Disease Research Fields Source Classification	Endogenous Metabolite
Quercetin 3,7-dimethyl ether, isolated from Croton schiedeanus Schlecht, has a NO/cGMP pathway-related profile, with increased vasorelaxant activity .

HY-121381

Kuraridine	Chalcones Flavonoids Classification of Application Fields Leguminosae Other Diseases Phenols Polyphenols Sophora flavescens Aiton Plants Disease Research Fields Source Classification	Phosphodiesterase (PDE)
Kuraridine is a prenylated flavonol extract from the roots of Sophora flavescens. Kuraridine has an inhibitory effect on cGMP specific phosphodiesterase type 5 (PDE5) (IC₅₀=0.64 μM) .

HY-18252A

Avanafil dibenzenesulfonate TA1790 dibenzenesulfonate	Cardiovascular Disease Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite
Avanafil (TA-1790) dibenzenesulfonate is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil dibenzenesulfonate activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil dibenzenesulfonate inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil dibenzenesulfonate can be used for the research of erectile dysfunction and osteoporosis .

HY-N6256

Ilexsaponin B2	Cardiovascular Disease Aquifoliaceae Triterpenes Classification of Application Fields Terpenoids Plants Disease Research Fields Tabernaemontana elegans Stapf Source Classification	Phosphodiesterase (PDE)
Ilexsaponin B2 is a saponin isolated from the root of Ilex pubescens Hook. et Arn. Ilexsaponin B2 is a potent phosphodiesterase 5 (PDE5) and PDEI inhibitor with IC₅₀ values of 48.8 μM and 477.5 μM, respectively .

HY-Y0790R

Cuminaldehyde (Standard) p-Isopropylbenzaldehyde (Standard)	Structural Classification Ketones, Aldehydes, Acids Rudbeckia laciniata L. Umbelliferae Plants Endogenous metabolite Source Classification	α-synuclein Reference Standards
Cuminaldehyde Standard is the analytical standard of Cuminaldehyde. This product is intended for research and analytical applications. Cuminaldehyde is the main component of Cuminum cyminum and has multiple biological activities, including anti-inflammatory, anti-cancer, anti-diabetic, anti-injury, anti-neuropathy and antibacterial effects. Cuminaldehyde is an inhibitor of aldose reductase (IC₅₀= 0.00085 mg/mL) and α-glucosidase (IC₅₀=0.5 mg/mL). Cuminaldehyde also inhibits the fibrillation of α-synuclein and prevents its aggregation Cuminaldehyde can induce apoptosis in colon adenocarcinoma cells by targeting topoisomerase I and II. In addition, Cuminaldehyde also exerts anti-inflammatory activity by inhibiting lipoxygenase. Cuminaldehyde has a strong inhibitory effect on the growth of Aspergillus flavus and the biosynthesis of aflatoxin B1 (AFB1). Cuminaldehyde can exert anti-injury and anti-neuropathy effects by participating in opioid receptors, L-arginine/NO/cGMP pathways and anti-inflammatory effects. Cuminaldehyde has potential application value in the research of neurodegenerative diseases, cancer, diabetes and neuropathic pain diseases .

HY-B0442C

Vardenafil dihydrochloride	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Endogenous Metabolite Phosphodiesterase (PDE)
Vardenafil dihydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM respectively, while IC₅₀s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^- .

HY-B0442CR

Vardenafil dihydrochloride (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite Phosphodiesterase (PDE)
Vardenafil (dihydrochloride) (Standard) is the analytical standard of Vardenafil (dihydrochloride). This product is intended for research and analytical applications. Vardenafil dihydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM respectively, while IC50s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes - .

HY-B0442AR

Vardenafil hydrochloride (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Phosphodiesterase (PDE) Endogenous Metabolite Reference Standards
Vardenafil (hydrochloride) (Standard) is the analytical standard of Vardenafil (hydrochloride). This product is intended for research and analytical applications. Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes - .

HY-B0442R

Vardenafil (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Phosphodiesterase (PDE) Endogenous Metabolite
Vardenafil (Standard) is the analytical standard of Vardenafil. This product is intended for research and analytical applications. Vardenafil is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-B0442BR

Vardenafil hydrochloride trihydrate (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite Phosphodiesterase (PDE)
Vardenafil (hydrochloride trihydrate) (Standard) is the analytical standard of Vardenafil (hydrochloride trihydrate). This product is intended for research and analytical applications. Vardenafil hydrochloride trihydrate is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil hydrochloride trihydrate shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride trihydrate competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride trihydrate can be used for the research of erectile dysfunction, hepatitis, diabetes - .

HY-113469AR

Cyclic GMP sodium (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
Cyclic GMP sodium (Standard) is the analytical standard of Cyclic GMP sodium (HY-113469A). This product is intended for research and analytical applications. Cyclic GMP (cGMP) sodium, an important second messenger, is a major intracellular mediator of extracellular signals such as nitric oxide (NO) and natriuretic peptides (NPs). Effects of Cyclic GMP sodium occur through three main groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and PDEs. Cyclic GMP can inhibit both platelet adhesion and aggregation. cGAMP (Cyclic-GMP-AMP) (HY-12512), a conjugate of Cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses .

HY-18252R

Avanafil (Standard) TA1790 (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite
Avanafil (Standard) is the analytical standard of Avanafil. This product is intended for research and analytical applications. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-P1987

Mast cell degranulating peptide (28-49)	Natural Products Animals Source Classification	Calcium Channel
Mast cell degranulating peptide (28-49) is a depolarizing agent from bee venom, it can raise the content of *cGMP* level in mouse cerebellar slices .

HY-W049735R

N,N,O-Tridesmethylvenlafaxine (Standard)	Monophenols Phenols Endogenous metabolite Source Classification	Drug Metabolite Reference Standards Endogenous Metabolite
Vardenafil (dihydrochloride) (Standard) is the analytical standard of Vardenafil (dihydrochloride). This product is intended for research and analytical applications. Vardenafil dihydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM respectively, while IC50s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes - .

HY-129665

GS-389 (±)-O,O-Dimethylcoclaurine	Alkaloids Cocculus laurifolius DC. Plants Isoquinoline Alkaloids Menispermaceae Source Classification	Endogenous Metabolite
GS 389 ((±)-O,O-Dimethylcoclaurine) is a tetrahydroisoquinoline. GS-389 inhibites Cyclic AMP and cyclic AMP dependent phosphodiesterases from rat atrial and ventricular tissue. GS-389 relaxes the contraction induced by phenylephrine and high K ⁺ in rat aortic rings .

HY-N0081A

(-)-Praeruptorin A	Structural Classification Chrysanthemum × morifolium (Ramat.) Hemsl. Coumarins Phenylpropanoids Umbelliferae Plants Source Classification	Calcium Channel
(-)-Praeruptorin A is a nature product that could be isolated from the roots of Peucedanum praeruptorum Dunn. (-)-Praeruptorin A relaxes ileum and tracheal smooth muscles by activating *NO/cGMP* signaling pathway. (-)-Praeruptorin A has dramatically therapeutic effects on hypertension mainly through acting as a Ca ²⁺-influx blocker .

HY-N16054

Cochliomycin A (+)-Cochliomycin A	Microorganisms Macrolide Antibiotics Antibiotics Source Classification	Bacterial
Cochliomycin A ((+)-Cochliomycin A) can be isolated from Gorgonian-Derived Fungus Cochliobolus lunatus. Cochliomycin A has antifouling activity (EC₅₀: 1.2 μg/mL). Cochliomycin A inhibits barnacle larval settlement by stimulating the NO/cGMP pathway. Cochliomycin A also has moderate antibacterial activity against S. aureus .

HY-N7126R

Citronellal (Standard)	Structural Classification Ketones, Aldehydes, Acids Murraya paniculata (L.) Jack. Rutaceae Plants Source Classification	Reference Standards Potassium Channel
Citronellal (Standard) is the analytical standard of Citronellal. This product is intended for research and analytical applications.Citronellal is a monoterpene that can be found in the essential oils in various aromatic species of plants, with antiinflammatory and antinociceptive properties. Citronellal attenuates mechanical nociception, mediated in part by the NO-cGMP-ATP-sensitive K+ channel pathway. Citronellal induces reduction of spontaneuous activity, ataxia, analgesia, and sedation in vivo. Citronellal can attenuate mechanical nociception response in mouse model .

HY-Y0488AR

Formic acid ammonium (Standard) Ammonium formate (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards NO Synthase Calcium Channel Bacterial ATP Synthase
Formic acid ammonium (Standard) is the analytical standard of Formic acid ammonium. This product is intended for research and analytical applications. Formic acid ammonium is the ammonium salt form of formic acid, which is an endogenous metabolite. Formic acid ammonium activates the nitric oxide/cyclic guanosine monophosphate (NO/cGMP) signaling pathway in endothelial cells and inhibits calcium ion influx in vascular smooth muscle cells, resulting in vasomotor relaxation. Formic acid ammonium inhibits cytochrome C oxidase (CcO) and disrupts the electron transport chain, leading to ATP depletion. Formic acid ammonium can be used as a feed additive, which can lower the feed pH value, inhibit the growth of microorganisms (such as Escherichia coli, Salmonella), and extend the shelf life of the feed.

HY-N4246R

Bacopaside I (Standard)	Triterpenes Structural Classification Terpenoids Scrophulariaceae Plants Bacopa monnieri (Linn.) Wettst. Source Classification	Reference Standards PKC Akt PI3K Apoptosis Pregnane X Receptor (PXR) Monoamine Oxidase Aquaporin
Bacopaside I (Standard) is the analytical standard of Bacopaside I. This product is intended for research and analytical applications. Bacopaside I is an orally active aquaporin AQP1 inhibitor and PKC modulator with neuroprotective and anticancer activities. Bacopaside I specifically blocks the water channel and *cGMP*-gated ion channel activities of AQP1 without affecting AQP4, thereby inhibiting the migration of colon cancer cells expressing AQP1. Bacopaside I activates the Akt pathway by interacting with PI3K, specifically inhibits MAO-A, effectively alleviates neuron necrosis and apoptosis induced by oxygen-glucose deprivation, reduces oxidative stress, and regulates the surface expression of neuroreceptors. When combined with Bacopaside II (HY-N6016), Bacopaside I significantly reduces the viability, proliferation and invasion ability of breast cancer cells, and binds to the pregnane X receptor (PXR). Bacopaside I is applicable to the research of colon cancer, breast cancer, vascular dementia, cerebral ischemia and other related diseases .

HY-113972R

Methyl mycophenolate (Standard)	Structural Classification Monophenols Microorganisms Marine natural products Phenols Marine microorganism	Reference Standards Others
Avanafil (Standard) is the analytical standard of Avanafil. This product is intended for research and analytical applications. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

Species:	Human (8) Mouse (1)
Tag:	SUMO (1) His (7) Myc (1) GST (4)
Source:	HEK293 (1) Sf9 insect cells (5) E. coli (3)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P71591

	cGB-PDE Protein, Mouse (Myc, His) Pde5a; Pde5; CGMP-specific 3',5'-cyclic phosphodiesterase; EC 3.1.4.35; CGMP-binding CGMP-specific phosphodiesterase; CGB-PDE	Mouse	E. coli
	cGB-PDE protein regulates signal transduction by specifically hydrolyzing cto 5'-GMP, thereby controlling the intracellular concentration of cyclic nucleotides, particularly nitric-oxide-generated cGMP. cGB-PDE Protein, Mouse (Myc, His) is the recombinant mouse-derived cGB-PDE protein, expressed by E. coli , with N-His, C-Myc labeled tag.

HY-P701759

	PRKG2 Protein, Human (Active, sf9, GST) PRKG2; CGMP-dependent protein kinase 2; cGK 2; cGK2; CGMP-dependent protein kinase II; cGKII	Human	Sf9 insect cells
	PRKG2 protein is a key regulator that activates CFTR to promote intestinal secretion and affect bone growth. It phosphorylates CFTR, coordinating cGMP-dependent translocation in the jejunum. PRKG2 Protein, Human (sf9, GST) is the recombinant human-derived PRKG2 protein, expressed by sf9 insect cells , with N-GST labeled tag.

HY-P71234

	PRKG1 Protein, Human (HEK293, His) CGMP-Dependent Protein Kinase 1; cGK 1; cGK1; CGMP-Dependent Protein Kinase I; cGKI; PRKG1; PRKG1B; PRKGR1A; PRKGR1B	Human	HEK293
	PRKG1 is a serine/threonine protein kinase that mediates the NO/c signaling pathway and phosphorylates various cellular proteins. It affects platelet activation, smooth muscle contraction, cardiac function, central nervous system processes, etc. PRKG1 Protein, Human (HEK293, His) is the recombinant human-derived PRKG1 protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P702647

	PRKG1 Protein, Human (Active, sf9, GST) PRKG1; protein kinase CGMP-dependent 1; PKG; cGK; AAT8; PKG1; cGK1; cGKI; cGK 1; PRKG1B; PRKGR1B; cGKI-BETA; cGKI-alpha	Human	Sf9 insect cells
	PRKG1 is a serine/threonine protein kinase that mediates the NO/c signaling pathway and phosphorylates various cellular proteins. It affects platelet activation, smooth muscle contraction, cardiac function, central nervous system processes, etc. PRKG1 Protein, Human (sf9, GST) is the recombinant human-derived PRKG1, expressed by Sf9 insect cells, with GST labeled tag.

HY-P74647

	PDE2A Protein, Human (sf9, His) CGMP-dependent 3',5'-cyclic phosphodiesterase; CGS-PDE; PDE2A	Human	Sf9 insect cells
	PDE2A is a cGMP-activated cyclic nucleotide phosphodiesterase that exhibits dual specificity for the second messengers cAMP and cGMP, key regulators in various physiological processes. PDE2A exhibits higher efficiency by covering cAMP and plays an important role in cell growth and migration. PDE2A Protein, Human (sf9, His) is the recombinant human-derived PDE2A protein, expressed by Sf9 insect cells , with C-His labeled tag.

HY-P75963

	PDE9A Protein, Human (His) High affinity CGMP-specific 3',5'-cyclic phosphodiesterase 9A; PDE9A	Human	E. coli
	PDE9A is a phosphodiesterase that uniquely hydrolyzes second messengers with unparalleled specificity, particularly in the regulation of natriuretic peptide-dependent signaling in the heart, which is critical for the control of cardiac hypertrophy. Its specificity rules out effects on nitric oxide-dependent signaling in the heart. PDE9A Protein, Human (His) is the recombinant human-derived PDE9A protein, expressed by E. coli , with N-His labeled tag.

HY-P75961

	PDE3A Protein, Human (sf9, His-GST) CGMP-inhibited 3',5'-cyclic phosphodiesterase A; CGI-PDE A; PDE3A	Human	Sf9 insect cells
	PDE3A protein, a cyclic nucleotide phosphodiesterase, targets cAMP, cGMP, and cUMP, crucial in diverse physiological processes. In an E2/17beta-estradiol-induced pro-apoptotic pathway, E2 stabilizes the PDE3A/SLFN12 complex, leading to SLFN12 dephosphorylation and activating its pro-apoptotic ribonuclease activity. This pathway is implicated in tissues with high E2 concentrations, potentially contributing to processes like placenta remodeling. PDE3A Protein, Human (sf9, His-GST) is the recombinant human-derived PDE3A protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.

HY-P75962

	PDE9A Protein, Human (sf9, His-GST) High affinity CGMP-specific 3',5'-cyclic phosphodiesterase 9A; PDE9A	Human	Sf9 insect cells
	PDE9A is a phosphodiesterase that uniquely hydrolyzes second messengers with unparalleled specificity, particularly in the regulation of natriuretic peptide-dependent signaling in the heart, which is critical for the control of cardiac hypertrophy. Its specificity rules out effects on nitric oxide-dependent signaling in the heart. PDE9A Protein, Human (sf9, His-GST) is the recombinant human-derived PDE9A protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.

HY-P71597

	cGAS Protein, Human (His-SUMO) 1 Publications Verification C6orf150; cGAMP synthase; cGAS; CGAS_HUMAN; CGMP Synthase; Chromosome 6 open reading frame 150; Cyclic GMP-AMP synthase; h-cGAS; Hypothetical protein LOC115004; Mab 21 domain containing 1; Mab-21 domain-containing protein 1; MB21D1; MGC131892; MGC142166; MGC142168; OTTHUMP00000016743; OTTHUMP00000039330; protein MB21D1; Uncharacterized protein C6orf150	Human	E. coli
	The cGAS protein is a nucleotidyl transferase that crucially mediates innate immunity by catalyzing the formation of 2',3'-cGAMP from ATP and GTP upon binding to double-stranded DNA (dsDNA). As a DNA sensor, cGAS detects exogenous and endogenous DNA, triggering STING1 activation and type I interferon production. cGAS Protein, Human (His-SUMO) is the recombinant human-derived cGAS protein, expressed by E. coli , with N-6*His, N-SUMO labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-B0442AS

Vardenafil-d5 hydrochloride

Vardenafil-d₅ hydrochloride is deuterated labeled Vardenafil hydrochloride (HY-B0442A). Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-W767865

Cyclic GMP sodium-13C5

Cyclic GMP sodium- ¹³C₅ is the ¹³C-labeled Cyclic GMP sodium (HY-113469A). Cyclic GMP (cGMP) sodium, an important second messenger, is a major intracellular mediator of extracellular signals such as nitric oxide (NO) and natriuretic peptides (NPs). Effects of Cyclic GMP sodium occur through three main groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and PDEs. Cyclic GMP can inhibit both platelet adhesion and aggregation. cGAMP (Cyclic-GMP-AMP) (HY-12512), a conjugate of Cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses .

HY-W654000

Cyclic GMP-13C,15N2

Cyclic GMP- ¹³C, ¹⁵N₂ is ¹³C and ¹⁵N labeled Cyclic GMP (HY-113469). Cyclic GMP (cGMP), an important second messenger, is a major intracellular mediator of extracellular signals such as nitric oxide (NO) and natriuretic peptides (NPs). Effects of Cyclic GMP occur through three main groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and PDEs. Cyclic GMP can inhibit both platelet adhesion and aggregation. cGAMP (Cyclic-GMP-AMP) (HY-12512), a conjugate of Cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses .

HY-B0442S

Vardenafil-d5

Vardenafil-d₅ is deuterium labeled Vardenafil. Vardenafil is a selective, orally active, potent inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil shows selectivity over PDE1 (180 nM), PDE6 (11 nM), PDE2, PDE3, and PDE4 (>1000 nM). Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil can be used for the research of erectile dysfunction .

HY-18252S3

Avanafil-13C5

Avanafil- ¹³C₅ (TA1790- ¹³C₅) is ¹³C labeled Avanafil. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-18252S1

Avanafil-13C5,15N,d2

Avanafil- ¹³C₅, ¹⁵N,d₂ is ¹⁵N and deuterated labeled Avanafil (HY-18252). Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-18253S

Udenafil-d7
Udenafil-d₇ is the deuterium labeled Udenafil. Udenafil (DA8159) is a potent, selective and orally active phosphodiesterase type 5 (PDE5) inhibitor. Udenafil also inhibits cGMP hydrolysis and can be used for erectile dysfunction research .

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P87358

	PDE10A Antibody (YA7041) 5''-cyclic phosphodiesterase 10A antibody; cAMP and cAMP inhibited CGMP 3'5' cyclic phosphodiesterase 10A antibody; cAMP and cAMP-inhibited CGMP 3'' antibody; FLJ11894 antibody; HSPDE 10A antibody; HSPDE10A antibody; PDE 10A antibody; PDE10_HUMAN antibody; Pde10a antibody; Phosphodiesterase 10A antibody	WB, IHC-P, FC	Human, Mouse, Rat
	PDE10A Antibody (YA7041) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PDE10A.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-130530

AP-C5		Alkynes
AP-C5 displays selective inhibition of guanosine 3′,5′-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII) with a pIC₅₀ of 7.2, which can be used for the research of diarrheal disease . AP-C5 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

CGMP

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Natural
Products